435 related articles for article (PubMed ID: 21296780)
21. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
23. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
24. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial comparing the velocities of the antihypertensive effects on home blood pressure of candesartan and candesartan with hydrochlorothiazide.
Hosaka M; Metoki H; Satoh M; Ohkubo T; Asayama K; Kikuya M; Inoue R; Obara T; Hirose T; Imai Y;
Hypertens Res; 2015 Oct; 38(10):701-7. PubMed ID: 26041602
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial.
Zhu DL; Bays H; Gao P; Mattheus M; Voelker B; Ruilope LM
Clin Ther; 2012 Jul; 34(7):1613-24. PubMed ID: 22717420
[TBL] [Abstract][Full Text] [Related]
27. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
28. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
[TBL] [Abstract][Full Text] [Related]
29. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Fogari R; Mugellini A; Derosa G;
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
[TBL] [Abstract][Full Text] [Related]
33. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
35. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
Sever PS; Chang CL
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):25-30. PubMed ID: 11881062
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
Weir MR; Weber MA; Neutel JM; Vendetti J; Michelson EL; Wang RY
Am J Hypertens; 2001 Jun; 14(6 Pt 1):567-72. PubMed ID: 11411737
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of regression of hypertension using contemporary antihypertensive agents.
Sasamura H; Nakaya H; Julius S; Tomotsugu N; Sato Y; Takahashi F; Takeuchi M; Murakami M; Ryuzaki M; Itoh H;
Am J Hypertens; 2013 Dec; 26(12):1381-8. PubMed ID: 24190927
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
40. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
Ohishi M; Takagi T; Ito N; Tatara Y; Hayashi N; Shiota A; Iwamoto Y; Katsuya T; Rakugi H; Ogihara T
Hypertens Res; 2007 Dec; 30(12):1187-92. PubMed ID: 18344623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
